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The largest randomised controlled trial evaluating the results of lung volume 
reduction surgery (LVRS) was conducted by the National Emphysema Treatment 
Trial (NETT) that published a series of reports for outcomes up to 24 months. 
However, patient outcomes were difficult to interpret due to limitations in and the 
presentation of conventional statistical analyses applied to repeated measures 
(longitudinal) data.  
 
We aimed re-evaluated the results from NETT using longitudinal data methodology to 
report longer term outcomes to facilitate interpretation by clinicians and patients who 
are considering LVRS in the management of emphysema.  
 
Methods 
Trial data was released by the United States National Institute of Health and the 
United States National Heart, Lung and Blood Institute, and analysed using a mixed 
effects model. 5 year data was estimated and presented in the baseline units of the 
original measurement.  
 
Results 
The five-year differences in patients randomised to LVRS was a small but sustained 
improvements in lung function parameters of FEV1, FVC and RV of +1.4% 
(P<0.001), +3.44% ((P<0.001) and -19.49% (P<0.001) of the predicted values 
respectively. With regards to physiological parameter function, the five year 
difference in patients randomised to LVRS was an overall 0.89 Watt improvement in 
maximum workload (P=0.069), -4.12 improvement in shortness of breath score 
(P<0.001) and a 0.088 improvement in quality of well-being score (P=0.102).  
 
Conclusions 
Our results suggest that LVRS continues to have an important role in the management 
of patients with severe emphysema with long term benefits to lung function 
parameters and a sustained improvement to the relief of dyspnoea. 
 
Introduction 
The largest randomised controlled trial evaluating the results of lung volume 
reduction surgery (LVRS) was conducted by the National Emphysema Treatment 
Trial (NETT) that published a series of reports for outcomes up to 24 months.1-3  
 
A decade later, the effects of LVRS on patient outcomes remain difficult to interpret 
by the majority of clinicians and therefore impossible to explain to our patients due to 
limitations in limitations in the way the data has been presented. We cannot advise 
patients on either the degree of benefit nor the proportion of patients who respond 
according to conventional measures. The original paper focussed on mortality and the 
other patient related outcomes such as quality of life and breathlessness were difficult 
to interpret. The impact of the results was to significantly reduce referral for lung 
volume reduction surgery. Consequently there has been a dramatic decrease in the 
number of procedures performed despite its overwhelming efficacy in appropriately 
selected patients. 
 
The statistical analyses and time series outcomes depicted as multiple histograms in 
the NETT publication provide a good overview to a complicated question, but does 
not take into account complexities such as correlation structures (within patient, 
between patients and between groups) within longitudinal data and therefore cannot 
provide easily interpretable information such as the average effect of LVRS versus 
medical therapy with time. 
 
The purpose of this study is to re-evaluate the results from the NETT using 
longitudinal data methodology to report longer term outcomes interpretable by 
clinicians and patients who are considering LVRS in the management of emphysema.  
 
Methods 
Data was obtained by joint permission from the United States National Institute of 
Health and the United States National Heart, Lung and Blood Institute, and 
interrogated using longitudinal data analysis techniques to estimate the differences in 
the survivors of the 608 surgical and 610 medical participants on age, sex and height 
adjusted (percentage predicted) values for lung volumes. The entry criteria of the 
study and trial results have been previously published.1, 4  
 
For each response variable we applied a mixed effects model, with an expected 
population average incorporating components for the effects of medical and surgical 
treatments.5 The model allows interpretation of the effect of medical treatment as 
linear with a monthly rate of change. The difference between medical treatment and 
surgical is given by the sum of a parameter that represents the immediate effect of 
surgery and a non-linear term that allows for an exponential decay of the surgical 
effect. We did not specify a correlation structure between errors as we adopted a 
saturated model to account for this. A full description of the statistical methodology 
used in this paper can be obtained on request.  
 
To facilitate clinical interpretation, assessment of efficacy for each major outcome 
was plotted on the estimated values and differences in patients randomised to LVRS 
or medical therapy using measurement values of each reference test, in units of the 
original test results and displayed as a time series plot. 
 
Results 
Longitudinal measurements of lung function were evaluated in 1218 patients in the 
cohort at 6, 12, 24, 36, 48 and 60 months. The results have been presented in two 
formats, the first is a plot of the individual estimated values in each group and the 
adjacent plot is the difference between patients randomised to LVRS versus medical 
treatment. A summary of the estimated differences at the immediate and 5 year period 
is provided in table 1.  
 
For FEV1, in patients randomised to LVRS, there was an immediate improvement in 
compared to medical therapy with an estimated decline to baseline approximately 5 
years after randomisation with a residual difference of +1.47% of predicted in favour 
of LVRS at the 5 year interval (Figure 1). Similarly, all other parameters that 
experienced initial improvement showed evidence of returning to baseline (albeit at a 
varying rate) within the 5 year follow up interval. The differences RV/TLC ratio can 
be seen in Figure 2. Other mechanical effects such as residual volume (Figure 3), 
forced vital capacity (Figure 4) also showed evidence of returning towards baseline 
but remained at -19.49% predicted (P<0.001) and +3.44% predicted (P<0.001) in 
favour of LVRS at the 5 year time point.  
 
In patients randomised to LVRS exercise performance measured as maximum 
workload increased initially but effects returned to baseline by 5 years with a residual 
difference of +0.89 W (P=0.069) in favour of LVRS (Figure 5). The physiological 
effect of improving arterial oxygenation was sustained at +5.96 mmHg in favour of 
LVRS but the difference was no longer statistically significant at P=0.480 (Figure 6). 
Symptomatic improvements to shortness of breath was sustained at -4.12 points 
(P<0.001) in favour of LVRS (Figure 7) but the overall quality of well-being score 
was still in favour of LVRS although the difference at the 5 year interval was small at 
0.09 and not statistically significant (Figure 8).  
 
Discussion 
Longitudinal data analysis is now an established sub-specialist area of statistics and 
regarded as a breakthrough method in the analysis of repeated measures data.6 
Application of this technique for the first time on the NETT data has revealed a 
number of insightful observations.  
 
The effects of LVRS in general have been evaluated in three broad outcomes, 
survival, lung function and quality of life. Data from the original NETT had revealed 
no difference in overall survival, however identified a sub-group of patients with 
upper lobe predominant heterogeneous emphysema and low baseline exercise 
capacity who are expected to derive a survival advantage with LVRS.1 
 
In this study, we profile the time differences in lung function measures between the 
two groups and categorise them as lung function and quality of life outcomes. The 
lung function improvements of LVRS such as immediate increase in FEV1, FVC, 
reduction in RV, TLC and RV/TLC ratio support the efficacy of LVRS as surgical 
therapy. The improvements however, the increments each show a tendency to return 
to baseline, albeit at different rates. The improvements to exercise work load seem to 
mirror that of the mechanical lung function results.  
 
The increase in PaO2 appeared sustained but was not statistically significant at the 5 
year interval. Detailed analyses of the LVRS study from our institution identified that 
the increase in Kco (the transfer factor for carbon monoxide) paralleled that of the 
arterial oxygenation, suggesting that the effects of LVRS may also be in part due to 
improvements in the redistribution of blood flow, by resecting severely diseased lung 
tissue.7 
 
Although no overall survival benefit has been demonstrated, lung function measures 
provide objective measures of benefit and we argue that patient related outcomes such 
as improvement to dyspnoea, quality of life and exercise capacity are more important. 
From the longer term results that we report, the most pertinent observation is the 
sustained improvement to the UCSD shortness of breath score (a five point difference 
has been reported as a reasonably minimally important difference8). 
 
Our results suggest that LVRS continues to have an important role in the management 
of patients with severe emphysema with long term benefits to lung function 
parameters and a sustained improvement to the relief of dyspnoea. LVRS should be 
undertaken with a view to improve patient symptoms rather than overall survival.  
  
Conclusions 
The effects of LVRS are an improvement to lung function and exercise workload that 
returning to baseline within a 5 year period. Although LVRS may not improve 
survival the procedure continues to have an important role in patients with severe 
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Table 1. Estimated immediate and 5 year effects on lung function parameters 
Response Estimated immediate 
effect 
p-value Estimated difference 
at 5 years 
p-value 
FEV1 (% predicted) +8.28 <0.001 +1.47 <0.001 
FVC (% predicted) +12.13 <0.001 +3.44 <0.001 
RV (% predicted) -55.08 <0.001 -19.49 <0.001 
TLC (% predicted) -15.09 <0.001 -5.24 <0.001 
RV/TLC -0.26 <0.001 -0.09 <0.001 
PaO2 (mmHg) +5.10 <0.001 +5.96 0.480 
Maximum Workload +7.97 <0.001 +0.89 0.069 
Shortness Breath 
Score 
-21.13 <0.001 -4.12 <0.001 
Quality of Well 
Being Score 
+0.16 <0.001 +0.09 0.102 





Figure 2. Results for the RV/TLC ratio  
 
 





Figure 4. Results for forced vital capacity  
 
 





Figure 6. Results for arterial oxygenation  
 
 











Figure 8. Results of quality of well being score 
 
 
 
